IRIS - Res&Arch Institutional Research Information System - Research & Archive

CHIASSERINI, DAVIDE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.253
AS - Asia 2.698
EU - Europa 2.303
SA - Sud America 487
AF - Africa 62
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 8.814
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.175
SG - Singapore 1.270
IT - Italia 513
IE - Irlanda 423
CN - Cina 392
BR - Brasile 384
HK - Hong Kong 338
RU - Federazione Russa 302
VN - Vietnam 246
FR - Francia 198
DE - Germania 197
UA - Ucraina 157
SE - Svezia 119
FI - Finlandia 118
BD - Bangladesh 88
KR - Corea 84
GB - Regno Unito 67
IN - India 53
RO - Romania 48
TR - Turchia 44
CA - Canada 43
IQ - Iraq 40
AR - Argentina 37
AT - Austria 29
NL - Olanda 29
PL - Polonia 20
CH - Svizzera 19
ZA - Sudafrica 19
JP - Giappone 18
SA - Arabia Saudita 18
VE - Venezuela 18
MX - Messico 17
ES - Italia 16
ID - Indonesia 16
PK - Pakistan 16
CL - Cile 14
CZ - Repubblica Ceca 12
EC - Ecuador 12
UZ - Uzbekistan 12
BE - Belgio 11
CO - Colombia 9
KE - Kenya 8
AE - Emirati Arabi Uniti 7
JO - Giordania 7
MA - Marocco 7
MY - Malesia 7
TN - Tunisia 7
LB - Libano 6
AO - Angola 5
IL - Israele 5
PH - Filippine 5
PY - Paraguay 5
DZ - Algeria 4
GR - Grecia 4
NP - Nepal 4
AZ - Azerbaigian 3
BO - Bolivia 3
CR - Costa Rica 3
DK - Danimarca 3
KZ - Kazakistan 3
LT - Lituania 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CG - Congo 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
EU - Europa 2
GT - Guatemala 2
JM - Giamaica 2
OM - Oman 2
PE - Perù 2
PS - Palestinian Territory 2
TJ - Tagikistan 2
TW - Taiwan 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BH - Bahrain 1
BW - Botswana 1
BZ - Belize 1
CI - Costa d'Avorio 1
CY - Cipro 1
FJ - Figi 1
GA - Gabon 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
HU - Ungheria 1
IR - Iran 1
KG - Kirghizistan 1
KI - Kiribati 1
LU - Lussemburgo 1
LV - Lettonia 1
Totale 8.800
Salva come PNG Salva come JPEG
Città #
Singapore 954
Dublin 421
Chandler 414
San Jose 355
Hong Kong 338
Ashburn 226
Perugia 214
San Mateo 183
Boardman 152
Moscow 132
Santa Clara 131
Beijing 121
Altamura 93
Lauterbourg 89
Seoul 83
Medford 81
Princeton 81
Munich 78
Los Angeles 76
Jacksonville 74
Wilmington 72
Ho Chi Minh City 71
Lawrence 68
The Dalles 62
New York 60
Dong Ket 59
Des Moines 39
Hanoi 38
Bucharest 34
Andover 31
Piscataway 30
Frankfurt am Main 28
São Paulo 28
Turku 28
Ann Arbor 27
Dallas 22
Helsinki 22
Redmond 22
Rome 22
Chennai 21
Denver 20
Izmir 19
Brooklyn 18
Milan 18
Orem 18
San Paolo di Civitate 18
Tokyo 18
Nuremberg 17
Council Bluffs 16
Johannesburg 15
Saint Petersburg 15
Warsaw 15
Baghdad 14
Phoenix 14
Vienna 14
Amsterdam 13
Montreal 13
Stockholm 13
Chicago 12
London 12
Buffalo 11
Guangzhou 11
Lappeenranta 11
Belo Horizonte 10
Brussels 10
Falkenstein 10
Hefei 10
Houston 10
Istanbul 10
Norwalk 10
Saint Louis 10
Toronto 10
Boston 9
Manchester 9
Shanghai 9
Tashkent 9
Atlanta 8
Columbus 8
Florence 8
Olomouc 8
Riyadh 8
Amman 7
Brasília 7
Caracas 7
Changsha 7
Charlotte 7
Curitiba 7
Dhaka 7
Nairobi 7
Poplar 7
Seattle 7
São José dos Campos 7
Campinas 6
Da Nang 6
Falls Church 6
Măgurele 6
Redwood City 6
Rio de Janeiro 6
Santiago 6
Terni 6
Totale 5.716
Salva come PNG Salva come JPEG
Nome #
Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration 172
Analisi del proteoma di carcinomi papillari della tiroide positivi per la mutazione BRAFV600E 146
Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients 133
Biochemical Studies on Human Ornithine Aminotransferase Support a Cell-Based Enzyme Replacement Therapy in the Gyrate Atrophy of the Choroid and Retina 132
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. 132
Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies 131
3-Bromopyruvate treatment induces alterations of metabolic and stress-related pathways in glioblastoma cells 130
Protein expression changes induced in murine peritoneal macrophages by Group B Streptococcus 127
Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies 126
Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis 126
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. 122
Cerebrospinal fluid biomarkers in Parkinson disease. 121
Effects of central and peripheral inflammation on hippocampal synaptic plasticity 120
Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson's disease. 119
Performance of Aβ1-40, Aβ1-42, Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment. 117
Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis 117
Persistent activation of microglia and NADPH drive hippocampal dysfunction in experimental multiple sclerosis 115
Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement 115
Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis 114
Crosstalk between long-term sublethal oxidative stress and detrimental inflammation as potential drivers for age-related retinal degeneration 114
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. 113
Identification of differentially expressed proteins in papillary thyroid carcinomas with V600E mutation of BRAF 110
Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. 109
Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia 109
Lysosomal enzyme activities in human brain 104
Proteomic analysis of papillary thyroid carcinoma reveals demodulation of mechanisms regulating cell proliferation, susceptibility to oxidative stress and cellular aggregation 103
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia 103
Extracellular Vesicles in Aging: An Emerging Hallmark? 101
Fingerprinting Alzheimer's Disease by 1H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid 101
L’analisi proteomica del carcinoma papillare della tiroide evidenzia modificazioni dello stato ossidoriduttivo e della struttura delle cellule tumorali 99
Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine 99
Mitochondria and the link between neuroinflammation and neurodegeneration. 98
Characterization of Two Populations of Prostasomes by Proteomics and Dynamic Light Scattering 97
Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics 96
CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. 95
Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: Do fresh vs frozen samples differ? 94
CSF Biomarkers in Parkinson's disease 93
Identification and Partial Characterization of Two Populations of Prostasomes by a Combination of Dynamic Light Scattering and Proteomic Analysis 93
Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis 92
Standardization and harmonization of distributed multi-center proteotype analysis supporting precision medicine studies 90
Erratum: Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis (Scientific Reports (2016) 6 (20926) DOI: 10.1038/srep20926) 89
Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies 89
A Practical Guide to Immunoassay Method Validation 87
Diagnostic utility of CSF α-synuclein species in Parkinson's disease: Protocol for a systematic review and meta-analysis 86
HOPS/TMUB1 Enhances Apoptosis in TP53 Mutation-Independent Setting in Human Cancers 85
Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease. 84
Differential protein expression in glioblastoma cells induced by 3-bromopyruvate 84
C1q is increased in cerebrospinal fluid-derived extracellular vesicles in Alzheimer's disease: A multi-cohort proteomics and immuno-assay validation study 83
Sistema immunitario e cefalee primarie 83
Origin of α-mannosidase activity in CSF 83
Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression 83
A prostate cancer proteomics database for swath-ms based protein quantification 83
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. 81
Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid. 81
Lysosomal enzymes in PD: further evidence is needed. 80
Proteomic biomarkers for the detection of endometrial cancer 80
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 79
Proteomic analysis of papillary thyroid carcinomas reveals demodulation of signal transduction pathways, increased resistance to oxidative stress and gain of invasive phenotype. 79
Molecular dynamic simulation of the catalytic domain of BRAF in response to activating and inactivating mutation 78
Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. 78
Proteomic changes induced by Group B Streptococcus in mouse peritoneal macrophages 78
Role of Lysosomal Enzymes in Parkinson’s Disease: Lesson from Gaucher’s Disease 78
Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study 78
CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. 78
Mortalin Inhibition in Experimental Parkinson's Disease 77
Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression 77
Comprehensive library generation for identification and quantification of endometrial cancer protein biomarkers in cervico-vaginal fluid 76
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays 75
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 74
Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. 74
Urinary Biomarkers and Their Potential for the Non-Invasive Detection of Endometrial Cancer 74
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 73
Structural dynamics shape the fitness window of alanine:glyoxylate aminotransferase 72
Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links 72
Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients 72
Proteomic analysis of cerebrospinal fluid extracellular vesicles: A comprehensive dataset 71
Immunological profile of silent brain infarction and lacunar stroke. 69
PROTEOMIC ANALYSIS OF EXTRACELLULAR VESICLES IN ALZHEIMER’S DISEASE CEREBROSPINAL FLUID 69
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 68
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers 63
Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study 63
No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF 63
Donor natural killer cells trigger production of beta-2-microglobulin to enhance post bone marrow transplant immunity 62
Modelli sperimentali 62
The use of missing values in proteomic data-independent acquisition mass spectrometry to enable disease activity discrimination 62
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 60
Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women 60
CSF neurosecretory proteins VGF and neuroserpin in patients with Alzheimer's and Lewy body diseases 60
Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia. 59
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 58
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 58
Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: electrophysiological evidence. 57
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 55
Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization 55
The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie 54
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 53
Enhancing mummy ‘palaeobiographies’ though the use of multidisciplinary techniques and approaches 53
Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: leveraging proteomics and machine learning for biomarker discovery 50
Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities 49
Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation 49
Totale 8.793
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.287
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.287
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202167 0 0 0 0 0 0 0 0 0 0 0 67
2021/2022717 8 124 15 30 9 9 4 193 45 47 102 131
2022/20231.391 87 272 16 118 96 141 3 67 535 3 38 15
2023/2024613 32 65 45 17 8 4 113 33 70 22 94 110
2024/20251.625 30 137 59 77 219 104 72 130 297 90 276 134
2025/20263.693 226 247 214 481 491 309 627 190 355 318 155 80
Totale 9.089